BioNTech SE

BioNTech SE engages in the development of novel medicines at the intersection of immunology and synthetic biology. Its product pipeline include BNT162b2, BNT161, BNT164, FixVac, iNeST, RiboMabs, CAR-T Cells, TCRs and Next-Gen CP Immunomodulators. The company was founded by Christopher Huber, Ozlem Tureci and Ugur Sahin on June 2, 2008 and is headquartered in Mainz, Germany.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

BioNTech reports robust 2022 earnings, eyes growth in oncology and infectious diseases

BioNTech's strong financial performance in 2022 sets the stage for continued growth in 2023, with a focus on expanding its vaccine portfolio, advancing oncology programs, and navigating the evolving landscape of COVID-19. The company's strategic priorities align with market demands for infectious disease and oncology solutions, positioning BioNTech for future success and profitability.

BioNTech posts robust Q1 results, eyes growth in vaccines and oncology

BioNTech's Q1 2023 performance reflects strong financial results and promising developments in its vaccine and oncology programs.
While facing challenges such as seasonal trends and data constraints, the company is strategically positioned to leverage opportunities in commercial planning and therapeutic advancements.
With a focus on synergistic partnerships and innovative technologies, BioNTech aims to maintain its competitive edge in the biopharmaceutical industry.
The company's commitment to enhancing existing platforms and exploring new growth avenues underscores its resilience and adaptability in a dynamic market environment.

BioNTech reports mixed Q2 results, focuses on innovation and growth

BioNTech's Q2 2023 performance reflects a mix of strong revenue generation and financial challenges, emphasizing the importance of strategic focus.
The company's strengths lie in its innovative collaborations, pipeline advancements, and preparedness for market demands, despite facing financial losses.
Navigating challenges in financial sustainability, market competition, and stakeholder communication will be crucial for BioNTech's future growth and success.

BioNTech adjusts revenue guidance amidst vaccine demand challenges

BioNTech's Q3 2023 performance reflected revenue challenges from lower COVID-19 vaccine demand and write-downs, prompting revised revenue guidance.
Despite challenges, the company showcased strengths in vaccine development, oncology advancements, and strategic cost management initiatives.
Opportunities lie in shared R&D expenses, long-term growth prospects from combination vaccines, and maintaining financial strength during market transition.

BioNTech reports strong Q4 earnings, eyes diversified product expansion

BioNTech is strategically investing in expanding its product portfolio while navigating uncertainties in COVID-19 vaccine revenues. The company aims to transform into a multiproduct company by 2030, focusing on oncology and infectious diseases.

BioNTech advances oncology pipeline, eyes growth amid financial challenges

BioNTech is making significant strides in its oncology pipeline, aiming for multiple product launches by 2026 and focusing on cancer vaccines and mRNA treatments.
While facing financial losses and short-term profitability challenges, the company remains optimistic about its growth trajectory and revenue potential.
Strategic investments in technology platforms, commercial readiness, and partnerships position BioNTech for sustainable growth and value enhancement.
Balancing cost control, revenue generation, and clinical execution will be crucial for BioNTech to capitalize on opportunities and navigate challenges effectively.

BioNTech reports Q2 progress in oncology pipeline amid financial challenges

BioNTech's Q2 2024 earnings call highlighted progress in oncology and COVID-19 vaccines, with total revenues of EUR 129 million but a net loss of EUR 808 million. The company remains focused on advancing innovative therapies and expanding its global manufacturing capabilities.

BioNTech reports robust Q3 earnings, focuses on oncology pipeline

BioNTech's Q3 2024 performance was strong, driven by COVID-19 vaccines and oncology trials.
While facing revenue challenges in certain regions, the company remains focused on growth.
Opportunities lie in advancing oncology pipeline and demonstrating product potential.
Maintaining a strong cash position provides flexibility for future investments.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

BioNTech SE operates as immunotherapy company, which engages therapies for cancer and other serious diseases. Its product pipeline include BNT162b2, BNT161, BNT164, FixVac, iNeST, RiboMabs, CAR-T Cells, TCRs and Next-Gen CP Immunomodulators. The company was founded by Christopher Huber, Oezlem Tuereci, and Ugur Sahin on June 2, 2008 and is headquartered in Mainz, Germany.

Inovio Pharmaceuticals

Moderna

Novavax

Telesis Bio Inc

Vaxart

We discuss six biotech/drug stocks, NVAX, VXRT, MRNA, TBIO, INO and BNTX that have more than doubled in 2020 on the back of their progress in coronavirus vaccine development.

6 Biotech/Drug Stocks Up Manifold in 2020 Thanks to COVID-19

Pfizer

Pfizer (PFE)/BioNTech(BNTX) won a deal for 100 million more doses of its COVID-19 vaccine in the United States.

Pfizer/BioNTech to Sell More COVID-19 Vaccine Doses to U.S.

Coronavirus vaccine stocks yo-yoed Wednesday as Pfizer won a deal for 100 million more doses in the U.S. and Moderna snagged authorization in Canada for people ages 18 and older. The post Vaccine Stocks Rebound On Pfizer's U.S. Deal, Moderna OK In Canada appeared first on Investor's Business Daily.

Vaccine Stocks Rebound On Pfizer's U.S. Deal, Moderna OK In Canada

The government still holds an option to get as many as 400 million more.

Pfizer and BioNTech to Supply Feds With 100 Million Additional Doses of Coronavirus Vaccine

Pfizer Inc. (NYSE: PFE) said on Wednesday that it struck a £1.48 billion deal with the U.S. government under which it will now deliver an additional 100 million doses of its COVID-19 vaccine by the end of July. The ongoing pandemic has so far infected more than 18 million people in the United States and caused over 332 thousand deaths.

Pfizer to deliver 100 million additional doses of its COVID-19 vaccine to the U.S. government

The shares of Pfizer Inc. (NYSE:PFE) are up 1.9% at $37.48 at last check, after the pharmaceutical company announced a second agreement with the U.S. government to supply an additional 100 million doses of its COVID-19 vaccine for $1.95 billion.

Pfizer Stock Surges After Vaccine Deal with U.S. Government

Here's what you need to know about the impact of Covid-19 to navigate the markets today.

Pfizer to Supply an Additional 100 Million Doses of Covid-19 Vaccine to U.S.

NEW YORK and MAINZ, GERMANY, December 23, 2020 (GLOBE NEWSWIRE) — Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced a second agreement with the U.S. government to supply an additional 100 million doses of the companies' COVID-19 vaccine from production facilities in the U.S. This agreement brings the total number of doses to be delivered to the U.S. to 200 million. The companies expect to deliver the full 200 million doses to Operation Warp Speed (OWS) by July 31, 2021. Consistent with the original agreement announced in July 2020 , the U.S. government will pay $1.95 billion for the additional 100 million doses.

Correction: Pfizer and BioNTech to Supply the U.S. with 100 Million Additional Doses of COVID-19 Vaccine

Pfizer Inc. and BioNTech SE announced Wednesday a second agreement with the U.S. government to supply an additional 100 million doses of its COVID-19 vaccine for $1.95 billion. That brings the total doses for the U.S. to 200 million.

Pfizer, BioNTech to supply U.S. with an additional 100 million doses of COVID-19 vaccine for about $2 billion

Pfizer Inc will supply the United States with 100 million additional doses of its COVID-19 vaccine by July next year, the U.S. drugmaker said on Wednesday.

Pfizer to supply U.S. with 100 million more COVID-19 shots by July

NEW YORK & MAINZ, Germany--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced a second agreement with the U.S. government to supply an additional 100 million doses of the companies' COVID-19 Vaccine from production facilities in the U.S. This agreement brings the total number of doses to be delivered to the U.S. to 200 million. The companies expect to deliver the full 200 million doses to Operation Warp Speed (OWS) by July 31, 2021. Consistent with the origi

Pfizer and BioNTech to Supply the U.S. with 100 Million Additional Doses of COVID-19 Vaccine

Pfizer is reportedly close to striking a deal with the Trump administration to supply tens of million more doses of its COVID-19 vaccine to the US in 2021, people familiar with the discussions told The New York Times Tuesday. The US government wants 100 million additional doses of Pfizer and its German partner BioNTech's vaccine between April to June, the Times reported. The drugmaker has said it could supply 70 million doses, the people said, provided it gets better access to manufacturing supplies through the Defense Production Act.

Pfizer and the Trump administration are reportedly close to agreeing 70 million extra vaccine doses for next year to plug a potentially massive shortfall in the US

Another deal with Pfizer would move the nation closer to the goal of vaccinating all Americans.

US close on deal with Pfizer for millions more vaccine doses

Pfizer Inc (NYSE: PFE) is nearing a deal with the outgoing President Donald Trump's administration to supply 100 million doses of its coronavirus vaccine to the United States, the Wall Street Journal reported Tuesday. What Happened: The U.S. government would pay Pfizer $2 billion as per the terms of the deal, under consideration, and the drugmaker would provide the vaccine doses by July, people familiar with the matter told the Journal.

Pfizer Nears Deal To Supply Another 100M COVID-19 Vaccine Doses To US By July

The government had the opportunity to secure 600 million doses under an agreement signed in July.

Report: Trump Administration Nears Deal For Additional Pfizer Vaccine Doses

Some troubling developments with the coronavirus in Europe have investors worried.

Why BioNTech Dived on Tuesday

The U.S. government is close to a deal with Pfizer for up to an additional 100 million doses of its coronavirus vaccine, a source told CNBC's Meg Tirrell on Tuesday.

Pfizer nears deal with U.S. government for more Covid vaccine doses, source says

BioNTech's boss said he is confident the company's COVID-19 vaccine will work against the new strain of coronavirus, but more tests were needed to be certain

BioNTech boss says more tests needed to see if vaccine protects against new COVID-19 strain

Germany's BioNTech says it needs only six weeks to create a coronavirus vaccine targeting the mutated virus rampaging across the U.K. But BioNTech stock crumbled Tuesday, despite the news. The post BioNTech CEO: It's Highly Likely Covid Vaccine Will Work On U.K. Strain appeared first on Investor's Business Daily.

BioNTech CEO: It's Highly Likely Covid Vaccine Will Work On U.K. Strain

Even with the relief brought by the conditional approval of two coronavirus vaccines, a more virulent and contagious variant of the virus in the U.K. has emerged.  Pfizer Inc. (NYSE: PFE), with its German partner BioNTech SE – ADR (NASDAQ: BNTX), and Moderna Inc (NASDAQ: MRNA) are the two companies that have received approval for emergency use of their respective investigational vaccines.

Moderna, Pfizer Testing Coronavirus Vaccine Against New Strain

Pfizer (PFE)/BioNTech's (BNTX) COVID-19 vaccine candidate is the first COVID-19 vaccine to be granted conditional authorization in Europe.

Pfizer/BioNTech COVID-19 Vaccine Gets Authorization in Europe

BioNTech's CEO said on Tuesday that while it is currently unclear whether the vaccine can protect against the new U.K. strain, it is “highly likely” the shot can protect against new variants.

Pfizer-BioNTech, Moderna Test Vaccines Against New Covid-19 Variant Spreading Across U.K.

It might seem like it, based on the stock's recent performance.

Is Pfizer's COVID Vaccine Growth Story Already Over?

The Pfizer-BioNTech vaccine has landed in the tiny-island nation after it was approved for distribution last week.

Singapore is first Asian country to receive batch of Pfizer's Covid-19 vaccine

Ugur Sahin, CEO of BioNTech SE (NASDAQ: BNTX) — the German partner of Pfizer Inc (NYSE: PFE) — expressed confidence that two companies' jointly-developed vaccine is effective against a new mutation of COVID-19, Reuters reported Monday.  What Happened: Sahin told Germany's Bild TV that BioNTech would look into the mutation that has emerged out of the United Kingdom in the coming days and viewed the matter “with a degree of soberness,” as per Reuters.

News for BioNTech SE Stock (BNTX)